UnitedHealthcare Releases Coverage Detail of Sarepta Therapeutics (SRPT) Exondys 51
Get Alerts SRPT Hot Sheet
Join SI Premium – FREE
UnitedHealthcare released its official coverage for Sarepta Therapeutics (NASDAQ: SRPT) Exondys 51 (eteplirsen)
Exondys 51 (eteplirsen) may be covered for:1
- The treatment of Duchenne muscular dystrophy (DMD) in patients who meet all of the following criteria:
- a. For initial therapy, all of the following:
- (1) Diagnosis of Duchenne muscular dystrophy AND
- (2) Submission of medical records (e.g., chart notes, laboratory values) confirming the mutation of the DMD gene is amenable to exon 51 skipping.1,2 AND
- (3) Exondys 51 dosing for DMD is in accordance with the United States Food and Drug Administration approved labeling: maximum dosing of 30 mg/kg infused once weekly. AND
- (4) Initial authorization will be for no more than 4 weeks.
- b. For continuation therapy, all of the following:
- (1) Exondys 51 dosing for DMD is in accordance with the United States Food and Drug Administration approved labeling: maximum dosing of 30 mg/kg infused once weekly. AND
- (2) Reauthorization will be for no more than 6 months Exondys 51 will not be covered for other forms of muscular dystrophy1
- (1) Exondys 51 dosing for DMD is in accordance with the United States Food and Drug Administration approved labeling: maximum dosing of 30 mg/kg infused once weekly. AND
- a. For initial therapy, all of the following:
Exondys 51 will not be covered for other forms of muscular dystrophy.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Emergent BioSolutions (EBS) Continues to Broaden Access, Awareness and Availability of NARCAN Nasal Spray
- Merck (MRK) Announces EU Approval of KEYTRUDA Plus Chemotherapy for NSCLC
- Zai Lab (ZLAB) Partner Novocure (NVCR) Announces METIS Phase 3 Clinical Trial Met Primary Endpoint
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!